Hematological risk factors for coronary heart disease

Medical Principles and Practice

Volumn 11, Issue SUPPL. 2, 2002, Pages 56-62

  El Hazmi, Mohsen A F ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antithrombin III deficiency; Coronary heart disease; Factor V Leiden; Fibrinogen; Homocysteine; Protein C; Protein S; Prothrombin

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; VON WILLEBRAND FACTOR;

ANTITHROMBIN III DEFICIENCY; ARTERIOSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DYSFIBRINOGENEMIA; GENE MUTATION; GENETIC DISORDER; HUMAN; HYPERHOMOCYSTEINEMIA; INFECTION; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; THROMBOPHILIA;

EID: 0036438811     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066407     Document Type: Conference Paper

References (57)

1. La Rosa JC: Future cardiovascular endpoint studies: Where will the research take us? Am J Cardiol 1999;84:545-548.
2. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors: The Framingham Study. Circulation 1979;59:8-13.
3. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG: Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: The atherosclerosis risk in communities (ARIC) study. Ann Intern Med 2000;133:81-91.
4. Catanzaro AJ, Suen R: Clinical laboratory indicators of cardiovascular disease risk. Alt Med Rev 1996;1:185-194.
5. Rauch U, Osende JL, Fuster V, Badimon JJ, Fayad Z, Chesebro JH: Thrombus formation on atherosclerotic plaques: Pathogenesis and clinical consequences. Ann Intern Med 2000; 134:224-238.
6. Gensini GF, Comeglio M, Colella A: Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J 1998;19(suppl A):A53-61.
7. Berg K: Genetics of coronary heart disease and its risk factors. Ciba Found Symp 1987;130: 14-33.
8. Neufeld HN, Goldbourt U: Coronary heart disease: Genetic aspects. Circulation 1983;67:943-954.
9. Sing CF, Moll PP: Genetics of variability of CHD risk. Int J Epidemiol 1989;18:S183-S195.
10. Pereira MA, Schreiner PJ, Pankow JS, Williams RR, Higgins M, Province MA, Rao DC: The family risk score for coronary heart disease: Association with lipids, lipoproteins, and body habitus in a middle-aged biracial cohort. The ARIC study. Ann Epidemiol 2000;10:239-245.
11. Ince B, Bayram C, Harmanci H, Ulutin T: Hemostatic markers in ischemic stroke of undetermined etiology. Thromb Res 1999;96: 169-174.
12. Feinberg WM, Bruck DC, Ring ME, Corrigan JJ Jr: Hemostatic markers in acute stroke. Stroke 1989;20:592-597.
13. Takano K, Yamaguchi T, Uchida K: Markers of a hypercoagulable state following acute ischemic stroke. Stroke 1992;23:194-198.
14. Folsom AR: New 'risk factors' for atherosclerotic disease. Exp Gerontol 1999;4:483-490.
15. Feinberg WK, Erickson LP, Bruck D, Kittelson J: Hemostatic markers in acute ischemic stroke: Association with stroke type, severity and outcome. Stroke 1996;27:1296-1300.
16. Fisher M, Francis R: Altered coagulation in cerebral ischemia: Platelet, thrombin, and plasmin activity. Arch Neurol 1990;47:1075-1079.
17. Deguchi K, Deguchi A, Wada H, Murashima S: Study of cardiovascular risk factors and hemostatic molecular markers in elderly persons. Semin Thromb Hemost 2000;26:23-27.
18. Fon EA, Mackey A, Cote R, Wolfson C, Mellraith DM, Leclerc J, Bourque F: Hemostatic markers in acute transient ischemic attacks. Stroke 1994;25:282-286.
19. Omo N, Koyama T, Suehiro A, Oku K, Fujikake K, Kakishita E: Clinical significance of new coagulation and fibrinolytic markers in ischemic stroke patients. Stroke 1991;22: 1369-1373.
20. Redondo M, Watzke HH, Stucki I, Sulzer I, Biasiutti FD, Binder BR, Furlan M, Lammle B, Wuillemin WA: Coagulation factors II, V, VII, and X, prothrombin gene 20210G-A transition, and factor V Leiden in coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19:1020-1025.
21. Cushman M, Lemaitre LH, Kuller LH, Psaty BM, Macy EM, Sharrett AR, Tracy RP: Fibrinogen activation markers predict myocardial infarction in the elderly: The cardiovascular health study. Arterioscler Thromb Vasc Biol 1999;19:493-498.
22. Ehrenforth S, von Depka Prondsinski M, Aygoren-Pursun E, Nowak-Gottl U, Scharrer I, Ganser A: Study of the prothrombin gene 20201 GA variant in FV: Q(50-6)carriers in relationship to the presence or absence of juvenile venous thromboembolism. Arterioscler Thromb Vasc Biol 1999;19:276-280.
23. Giannitsis E, Siemens HJ, Mitusch R, Tettenborn I, Wiegand U, Schmucker G, Sheikhzadeh A, Stierle U: Prothrombin fragments F 1 + 2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis. Int J Cardiol 1999;68:269-274.
24. Gardemann A, Arsic T, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W: The factor II G20210A and factor V G1691A gene transitions and coronary heart disease. Thromb Haemost 1999;81:208-213.
25. Nguyen A: Prothrombin G20210A polymorphism and thrombophilia. Mayo Clin Proc 2000;75:595-604.
26. Corral J, Gonzalez-Conejero R, Lozano ML, Rivera J, Heras I, Vicente V: The venous thrombosis risk factor 20210A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol 1997;99:304-307.
27. Svensson PJ, Dahlback B: Resistance to activated protein C is a basis for venous thrombosis. N Engl J Med 1994;330:517-522.
28. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
29. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1993;332:912-917.
30. Ueland PM, Refsun H, Stabler SP, Mailinow MR, Andersson A, Allen RH: Total homocysteine in plasma or serum: Methods and clinical applications. Clin Chem 1993;39:1764-1779.
31. Finkelstein JD, Martin JJ, Harris BJ: Methionine metabolism in mammals: The methionine sparing effect of cystine. J Biol Chem 1988; 263;11750-11754.
32. McCully KS: Vascular pathology of homocysteine: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128.
33. Ueland PM, Refsum H: Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease and drug therapy. J Lab Clin Mod 1989;114:473-501.
34. McCully KS: Homocysteine and vascular disease. Nat Med 1996;2:386-389.
35. Kang SS, Wong PW, Malinow M: Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Am Rev Nutr 1992;12:279-298.
36. Deloughery TG, Evans A, Sadeglu A, McWilliams J, Henner WD, Taylor LM Jr: Common mutations in methylene tetrahydrofolate reductase: Correlation with homocysteine metabolism and late onset vascular disease. Circulation 1996:3074-3078.
37. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324:1149-1155.
38. Glueck CJ, Shaw P, Lang JE, Tracy T, Steve-Smith L, Wang Y: Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemia patients. Am J Cardiol 1995; 75:132-136.
39. Amesen E, Refsum H, Bonaa KH, et al: Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-709.
40. Welch GN, Loscalzo J: Homocysteine and atherosclerosis. N Engl J Med 1998;338:1042-1049.
41. Anand A: Fibrinogen and cardiovascular risk. Ann Intern Med 1993;119:1222-1223.
42. Ernst E: Fibrinogen: An important risk factor for atherosclerotic diseases. Ann Med 1994;26:15-22.
43. Hamsten A, Iselius L, de Faire U, Blomback M: Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987;ii:988-991.
44. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, Rasmussen ML, Wu KK: Prospective study of markers of hemostatic function with risk of ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999;100:736-742.
45. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG: Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000;133:81-91.
46. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U: Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000;20:2019-2023.
47. Wiman B: Plasminogen activator inhibitor I (PAI) in plasma: Its role in thrombotic disease. Thromb Haemost 1995;74:71-76.
48. Altes A, Abellan MT, Mateo J, Avila A, Marti-Vilalta JL, Fontcuberta J: Hemostatic disturbances in acute ischemic stroke: A study of 86 patients. Acta Haematol 1995;94:10-15.
49. Takano K, Yamaguchi T, Uchida K: Markers of a hypercoagulable state following acute ischemic stroke. Stroke 1992;23:194-198.
50. Wu KK: Genetic markers: Genes involved in thrombosis. J Cardiovasc Risk 1997;4:347-352.
51. Sansores-Garcia L, Majluf-Cruz A: Arterial and venous thrombosis associated to combined deficiency of protein C and antithrombin III. Am J Hematol 1998;57:182-183.
52. Saleun S, De Moerloose P, Bura A, Aiach M, Emmerich J: A novel nonsense mutation in the antithrombin III gene (Cys-4→stop) causing recurrent venous thrombosis. Blood Coagul Fibrinolysis 1996;7:578-579.
53. Maass M: Persistence of Chlamydia pneumoniaein human atherosclerotic plaques material: Evidence and consequences. Herz 1998;23:178-184.
54. Mehra JL, Saldeen TG, Rand K: Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998;31:1217-1225.
55. Mazzoli S, Tofani N, Fantini A, Semplici F, Bandini F, Salvi A, Vergassola R: Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up. Am Heart J 1998;135:15-20.
56. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Maunter B: Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: The final report of the ROXIS study. Eur Heart J 1999;20:121-127.
57. Pasceri V, Cammarota G, Patti G, Cucco L, Gasbarrini A, Grillo RL, Fedeli G, Gasbarrini G, Maseri A: Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998;97:1675-1679.